Full-Time

Senior Manager

Value Stream CAR-T Manufacturing

Posted on 8/4/2025

Deadline 8/4/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$127.8k - $154.8k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Summit, NJ, USA

In Person

Category
Biology & Biotech (7)
, , , , , ,
Requirements
  • Extensive knowledge of EHS and cGMPs and the know–how to work and manage within a regulated environment.
  • Demonstrates aptitude for biotechnology principles and manufacturing systems.
  • Demonstrated proficiency in selection of team and effectively managing personnel issues.
  • Adaptable to a fast paced, complex and ever-changing business environment.
  • Knowledge of lean manufacturing principles required. Green belt certified is a preference.
  • Excellent communication skills (EN).
  • Bachelor’s degree in related field is preferred, or equivalent in work experience, and the ability to think and lead strategically.
  • 7+ years of relevant manufacturing experience.
  • Minimum of 5 years leadership experiences including the management of direct reports required.
Responsibilities
  • Is accountable to ensure their Manufacturing Managers and their WCT members execute the manufacturing of Cell Therapy products according to Current Good Manufacturing Practices (cGMP’s) following the current, approved Standard Operating Procedures (SOPs) and Work Instructions (WIs).
  • Responsible to own, review, author, or approve SOP, WI, master batch records.
  • Takes personal responsibility to work safely and to ensure their managers and WCT members do the same.
  • Performs regular safety Gemba walks, knows the hazards associated with their work and demonstrates safe behavior.
  • Operates and maintains equipment to prevent injuries or incidents.
  • Is accountable for the Production Records produced by their Manufacturing Managers and WCT members.
  • Performs batch record reviews (BRR) or Electronic Batch Record review by exception.
  • Ensures that all documentation produced by their Managers and WCTs follows the ALCOA+ principles.
  • Ensures the documentation produced by their Manufacturing Managers and WCT members is right first time, and all records and logbooks are complete and accurate.
  • Resolve documentation errors and corrections as needed to enforce manufacturing turn-around-times.
  • Is required to perform Cell Therapy manufacturing to maintain hands on expert knowledge of each Unit Operation, demonstrate what good execution looks like to new managers and WCT members and when necessary, back fills for absent team members or makes up the execution resource requirements to meet the production schedule.
  • Supports Material Review Board (MRB) data collection and provides process expertise when required to support the MRB decision making process.
  • Rotates weekend coverage for manufacturing operations and is first line support for any technical or manufacturing issues during weekend coverage.
  • Continues to develop expertise in the field of CAR – T Manufacturing and regulatory requirements that pertain CAR T manufacturing.
  • Is responsible to provide the Production Scheduling team with information (daily, weekly monthly) on the availability of their managers and WCT production resources and tracks/maintains records of all team members actual availability vs planned or unplanned absence due to holidays, sickness or other reasons.
  • Is responsible to hire personnel that meet job description criteria and BMS values and sustain the manufacturing culture and that meet budgetary and fiscal requirement.
  • Sets their managers and WCTs priorities and adjusts as necessary to track the site and or functional priorities, establishes the WCT goals and is responsible to monitor, measure and assess the performance/completion of the WCT manufacturing activities and goals.
  • Reports out performance metrics and goal progress daily, weekly, monthly in functional and site Tier meetings and the site metric control plans.
  • Ensures that their Manufacturing Managers and their WCTs have the appropriate level of training necessary for CAR-T GMP manufacturing in a multi-product commercial facility.
  • Is responsible to maintain their Manufacturing Managers, themselves, and WCTs training compliance at the required 100% on-time completion rate.
  • Ensures that their Manufacturing Managers and their WCT members are proficient and qualified to perform the manufacturing tasks before doing so.
  • Monitors team training due dates and maintains the trained status of their Manufacturing Managers and WCT members by ensuring appropriate time is allocated to training activities.
  • Immediately disqualifies personnel from GMP tasks if observed to not comply with SOPs, Wis, or batch records, including safety trainings.
  • Is responsible to build high performing WCTs comprising of Manufacturing Managers, Operators, Team Leads and Supervisors.
  • Recruits exceptional people, conducts interviews, reviews candidates’ suitability and provides meaningful feedback to Talent Acquisition and HR partners during the recruitment process.
  • Is responsible to create and maintain Workday profiles for all new hired staff.
  • Is responsible to administer the annual performance review process, differentiating performance between team members.
  • Gives recognition when deserved and guidance to improve poor performance or behavior not aligned with the BMS values.
  • Conducts regular 1:1 meeting with each Manufacturing Manager to mentor, develop and motivate them.
  • Cascades relevant company information and takes time to help team members with their professional development including seeking out potential career development opportunities.
  • Creates a culture of learning via discussion of deviations, safety incidents, and provides meaningful, timely, and accurate coaching during processing.
  • Develops cross-functional relationships with Quality Shop Floor, Warehouse, Supply Chain and Manufacturing Science & Technology, QC Laboratories, QA Doc Control and Training & Learning Organization to sustain and maintain compliant manufacturing processes.
  • Leads troubleshooting activities for their WCTs and is a Deviation Business Process Owner (BPO) or Business Technical Approver (BTA) for deviation approvals occurring in their area.
  • Oversees their WCTs to ensure they author clear, concise, and factually complete descriptions of events that led to the deviation and ensures timely entry of the deviation record information in the system.
  • Maintains deviation metrics and ensures deviation awareness for the WCTs across all shifts, Pareto’s out worst or repeat causes of deviations and ensures close out of all deviations on time.
  • Works proactively with their Manufacturing Managers and WCTs to reduce the number of deviations occurring and to eliminate repeat causes of deviations.
  • Is accountable to drive continuous improvement to prevent repeat deviations.
  • Reviews the Manufacturing Managers (No Impact) deviation records and ensures they are a clear and concise representation of the event and that all entries comply with ALCOA+ documentation principles.
  • Reports out deviation progress, maintains their deviation metrics, Pareto’s out worst or repeat causes of deviations and closes out all deviations on time.
  • Ensures their Manufacturing Managers maintain deviation closure rate (on-time – 2 days prior to due date).
  • Provides reinforcement discussion or coaching as needed to build WCT expertise.
  • Participates in CAPAs, Change Controls and Projects from time to time as required by the business and directed by senior management.
  • Implements or holds Managers responsible for the implementation of CAPAs prior to due date.
  • Participates in CAPA, Change Control meetings and defines, agrees, or owns CAPAs, Change Controls for manufacturing.
  • Effectively controls expenses within their influence (OT, Supplies, T&E).
  • Is responsible to facilitate and lead weekly Tier meetings with each of the Manufacturing Managers and cross functional partners using the site standard Tier meeting tools.
  • Is responsible to facilitate and lead weekly Performance Review meetings with each of the Manufacturing Managers and cross functional partners using the site standard Performance review meeting tools and cascading KPIs/Metrics.
  • Is responsible to participate in the monthly Manufacturing Performance Review meetings (facilitated by the Manufacturing Associate Directors)
  • Is responsible to participate in the weekly Production Scheduling meeting to provide a summary of their WCTs training status and resource availability/constraints to be able to execute the proposed production plan in the days / week ahead.
  • Is responsible to participate in the weekly Deviation, CAPA, and Change Control meetings to provide status updates on the quality records owned by them.
  • Attends the daily cross-functional manufacturing meeting providing summary of previous day activities, successes, or communicates equipment outages or processing delays.
Desired Qualifications
  • Advanced degree preferred.

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

INACTIVE